Search Patents
  • MULTIPLE ANTIGENIC PEPTIDE AGAINST CORONAVIRUS AND IMMUNOSTIMULATING COMPOSITION CONTAINING THE SAME
    Publication number: 20230218742
    Abstract: The present invention provides a vaccine against a coronavirus. According to the present invention, there is provided a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 or a partial peptide of a coronavirus spike protein consisting of the amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 1 and a multiple antigen peptide containing a plurality of any of these peptides.
    Type: Application
    Filed: May 21, 2021
    Publication date: July 13, 2023
    Applicants: RIKEN, ANIMAL ALLERGY CLINICAL LABORATORIES INC.
    Inventors: Kenichi MASUDA, Takashi SAITO
  • Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments
    Patent number: 10975139
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 13, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, Alina Baum, Gang Chen, Cindy Gerson, Johanna Hansen, Tammy Huang, Christos Kyratsous, Wen-Yi Lee, Marine Malbec, Andrew Murphy, William Olson, Neil Stahl, George D. Yancopoulos
  • Stabilized coronavirus spike (S) protein immunogens and related vaccines
    Patent number: 11845777
    Abstract: The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: December 19, 2023
    Assignee: The Scripps Research Institute
    Inventors: Linling He, Jiang Zhu, Ian A. Wilson
  • CORONAVIRUS VACCINES
    Publication number: 20230241201
    Abstract: The invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding the S1 and S2 subunits of a coronavirus Spike protein is located, such that a chimeric virus is expressed.
    Type: Application
    Filed: March 1, 2021
    Publication date: August 3, 2023
    Inventors: Kai DALLMEIER, Johan NEYTS, Lorena SANCHEZ FELIPE, Hendrik, Jan THIBAUT, Dominique VAN LOOVEREN, Thomas VERCRUYSSE
  • ANTIVIRUS PROTEINS HAVING A KRINGLE 5 SUBUNIT
    Publication number: 20210324047
    Abstract: COVID-19 results from the infection of the SARS-CoV-2 virus and has spread quickly to literally infected the world. Although coronavirus spike proteins can recognize a broad range of host cell-surface proteins, inhibiting spike protein binding to a survival factor called GRP78 results in a significant reduction in SARS-CoV-2 attachment, entry and replication in lung and kidney cells. This inhibition is accomplished with a novel type of inhibitor that potently blocks the binding of SARS-CoV-2 spike protein and whole virus to surface-bound GRP78. These novel GRP78 inhibitors also down regulate cytokines (IL10, IL6), immune co-inhibitory checkpoint proteins (PD-L1, B7H3, B7H4), and up regulate immune co-stimulatory proteins (MHC-II, CD-86) resulting in the reduction of the immune suppressive nature of infected lung alveolar epithelial cells in vitro and in vivo. Finally, these novel GRP78 inhibitors inhibit the hyperfibrinolysis of infected lung cells by reducing the activation of plasmin on cell surfaces.
    Type: Application
    Filed: April 20, 2021
    Publication date: October 21, 2021
    Inventor: Donald J. DAVIDSON
  • Coronavirus Disease 2019(COVID -19) Recombinant Spike Protein Forming Trimer, Method for Mass Producing Recombinant Spike Protein in Plants, and Method for Preparing Vaccine Composition on Basis Thereof
    Publication number: 20230203101
    Abstract: The present invention relates to a recombinant spike protein of the COVID-19 virus forming a trimer and a method for mass-producing the recombinant spike protein, and more specifically to a method for designing a recombinant gene expressing a recombinant spike protein of the COVID-19 virus forming a trimer for the purposes of enhancing immunogenicity and effective antigen delivery, and a method for mass-producing the recombinant spike protein in plants.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 29, 2023
    Applicants: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION, KOREA NATIONAL INSTITUTE OF HEALTH, BIOAPPLICATIONS INC
    Inventors: In Hwan HWANG, Shijian SONG, Rezaul Islam Khan MD, Haiping DIAO, Eun Ju SOHN, Bo Hwa CHOI, Jang Hoon CHOI, Eun Young JANG, Young Jae LEE
  • Method of treating coronavirus infections
    Patent number: 11166999
    Abstract: The present application relates to a compositions and methods comprising or expressing a MOMO30 protein derived from Momordica balsamina. The MOMO30 protein is about 30 kDa in size, binds coronavirus S protein, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to coronavirus spike (S) protein, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by a coronavirus or alleviating symptoms in coronavirus infected patients and comprises the amino acid sequence of SEQ ID NO: 1. The MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating viral infections by coronaviruses and others.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: November 9, 2021
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Michael Powell, Erick Vidjin′ Agnih Gbodossou
  • ANTI-CORONAVIRUS VACCINES
    Publication number: 20220047696
    Abstract: The invention provides stable coronavirus spike proteins. Immunogenic compositions comprising same and the methods of using these immunogenic compositions are also provided.
    Type: Application
    Filed: July 30, 2021
    Publication date: February 17, 2022
    Inventors: Eric Todd Baima, Yulia Burakova, Paul Joseph Dominowski, Steven Alan Dunham, Nicole Lynn Hainer, John Morgan Hardham, Mahesh Kumar, Jason John Millership, Duncan M. Mwangi, Sharath K. Rai, Sharon Marie Wappel, Dennis Lee Foss
  • Corona-virus-like particles comprising functionally deleted genomes
    Publication number: 20050186575
    Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines therefor. Methods are shown for at least in part inhibiting anti-parallel coiled coil formation of a coronavirus spike protein which methods include decreasing the contact between heptad repeat regions of the coronavirus spike protein. The invention provides a peptide comprising a heptad repeat region of a coronaviral spike protein and/or a functional fragment and/or a derivative thereof. The invention also provides antibodies and compounds inhibiting coronaviral infection of cells, and/or cell-to-cell fusion. The invention also includes heptad repeat regions and a fusion peptide of SARS-CoV.
    Type: Application
    Filed: December 30, 2003
    Publication date: August 25, 2005
    Inventors: Petrus Rottier, Berend Bosch
  • Neutralizing Antibodies that Bind the SARS-COV-2 S Protein
    Publication number: 20230406907
    Abstract: The present disclosure provides antigen-binding proteins, such as fully human antibodies, that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus and uses thereof. In various embodiments, the anti-spike protein antibodies are neutralizing antibodies that prevent binding of the SARS-CoV-2 coronavirus to a target cell expressing the ACE2 protein. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Also provided herein are nucleic acids and recombinant expression vectors that encode the anti-spike protein antibodies and antibody fragments disclosed herein and transgenic cells transected with such nucleic acids and expression vectors. Further provided are methods for preparing and using such anti-spike protein antibodies.
    Type: Application
    Filed: May 5, 2021
    Publication date: December 21, 2023
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Xia Cao, Lucy Lu, Ying Yan, Yanliang Zhang, Henry Hongjun Ji, Robert Allen
  • CORONAVIRUS PSEUDOVIRUS PACKAGING SYSTEM, PACKAGING METHOD THEREFOR, AND APPLICATION OF CORONAVIRUS PSEUDOVIRUS IN EVALUATING DISINFECTION EFFICACY
    Publication number: 20230332177
    Abstract: A packaging system for a coronavirus pseudovirus, including a vesicular stomatitis virus (VSV) vector in which Fluc and EGFP dual-reporter genes replace a GP gene, and packaging cell that expresses a coronavirus spike protein. The packaging system may quickly package pseudoviruses by using a one-step packaging method, and may be used in the research of coronaviruses such as COVID-19 (SARS-CoV-2), SARS (SARS-CoV) and MERS, and other viruses. The packaging system and thereby pseudovirus method may also be used to evaluate the efficacy of disinfectants by means of virus contamination distribution models, setting up scenarios, and sampling and testing steps.
    Type: Application
    Filed: June 15, 2021
    Publication date: October 19, 2023
    Applicant: FANTASIA BIOPHARMA (ZHEJIANG) CO. LTD
    Inventors: Frank Xiaofeng QIN, Zhiming WEI, Limei LONG, Renxiang YANG, Fan LI
  • MONOCLONAL ANTIBODY AGAINST S PROTEIN OF MERS-CORONAVIRUS, AND USE OF SAME
    Publication number: 20210238261
    Abstract: The present invention relates to a monoclonal antibody specifically recognizing a spike protein of MERS coronavirus (MERS-CoV) or a part of the protein, or a functional fragment thereof, wherein the monoclonal antibody, or functional fragment of the monoclonal antibody characterized in that it comprises polypeptide sequence selected from the group consisting of the following polypeptide sequences: a heavy chain comprising a complementarity determining region 1(CDR 1) amino acid sequence consisting of the sequence of SEQ ID NO: 1, a CDR2 consisting of the sequence of SEQ ID NO: 2 and a CDR 3 consisting of the sequence of SEQ ID NO: 3; and a light chain comprising CDR1 amino acid sequence consisting of the sequence of SEQ ID NO: 4, a CDR2 consisting of the sequence of SEQ ID NO: 5 and a CDR 3 consisting of the sequence of SEQ ID NO: 6.and uses thereof.
    Type: Application
    Filed: August 13, 2019
    Publication date: August 5, 2021
    Inventors: Hyung Joo KWON, Byoung Kwon PARK, Dong Bum KIM
  • COMPOSITIONS AND METHODS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) VARIANTS HAVING SPIKE PROTEIN MUTATIONS
    Publication number: 20220290221
    Abstract: Methods for the rapid detection of the presence of variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that contain mutations in the Spike (S) protein gene in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting SARS-CoV-2 variants containing S gene mutations and kits are provided that are designed for the detection of SARS-CoV-2 variants containing S gene mutations.
    Type: Application
    Filed: March 11, 2022
    Publication date: September 15, 2022
    Inventors: Chitra Manohar, Marcel R. Fontecha, Christopher David Santini, Eugene Spier, Jingtao Sun, Michelle Elizabeth Yee, Kalyani Mangipudi
  • METHODS OF PREVENTING OR TREATING CORONAVIRUS INFECTION AND REDUCING CORONAVIRUS INFECTION RATE IN VITRO WITH ANTIVIRAL COMPOSITION COMPRISING POLY(3,4-ETHYLENEDIOXYTHIOPHENE):POLY(STYRENE SULFONATE)
    Publication number: 20230321138
    Abstract: The present invention provides methods of preventing or treating coronavirus infection and reducing coronavirus infection rate in vitro with antiviral composition comprising poly(3,4-ethylenedioxythiophene):poly(styrene sulfonate) (PEDOT:PSS), wherein the PEDOT:PSS is selected from PEDOT:PSS aqueous solutions in various formulas. Specifically, the molar ratio of PEDOT to PSS in the PEDOT:PSS aqueous solution in the antiviral composition may be 1:1.5 to 1:6 and the resistivity of the PEDOT:PSS aqueous solution in the antiviral composition may be 100 ?/sq to 5×107 ?/sq. The antiviral composition is used to inhibit the binding between the spike protein of the coronavirus and the host cells with angiotensin-converting enzyme 2 (ACE2) on surface. The coronavirus may be SARS-CoV-2.
    Type: Application
    Filed: June 14, 2022
    Publication date: October 12, 2023
    Inventor: Ming-Han TSAI
  • ANTI COVID-19 THERAPIES USING NUCLEOCAPSID AND SPIKE PROTEINS
    Publication number: 20220023415
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 27, 2022
    Inventor: Thomas H. King
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20210283245
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Application
    Filed: May 26, 2020
    Publication date: September 16, 2021
    Inventors: Kayvan Niazi, Thomas King
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20230302121
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
    Type: Application
    Filed: May 4, 2023
    Publication date: September 28, 2023
    Applicant: NantCell, Inc.
    Inventors: Kayvan Niazi, Thomas H. King
  • CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLUTININ/ESTERASE
    Publication number: 20090081780
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.
    Type: Application
    Filed: September 26, 2008
    Publication date: March 26, 2009
    Applicant: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • VACCINE COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-CORONAVIRUS-2 INFECTION
    Publication number: 20240042008
    Abstract: The present invention provides a recombinant antigen protein for preventing SARS-coronavirus-2 infection, comprising a polypeptide derived from an S1 subunit of a spike protein of SARS-coronavirus-2 and a polypeptide constituting a tetanus toxin (TT) epitope P2 domain, and a vaccine composition comprising the same.
    Type: Application
    Filed: October 27, 2021
    Publication date: February 8, 2024
    Applicant: SK BIOSCIENCE CO., LTD.
    Inventors: Ki-weon SEO, Teawoo KWON, Eun-som KIM, Chi-Yong KIM, Yoonjae LEE, Seung-hye HONG
  • SINGLE DOMAIN ANTIBODIES THAT TARGET SARS-COV-2
    Publication number: 20230374116
    Abstract: The present invention relates to improved single domain antibodies that target SARS-CoV-2, multivalent polypeptides and fusion proteins comprising the single domain antibodies. The present invention also provides coronavirus binding molecules that bind two different epitopes on the receptor binding domain of a spike protein of a coronavirus. The coronavirus binding molecules are based on joining two antigen binding molecules together via a linker. The present invention provides the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in treating and/or preventing coronavirus, as well as the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in the detection and diagnosis of coronavirus using various methods, assays and kits.
    Type: Application
    Filed: September 14, 2021
    Publication date: November 23, 2023
    Inventors: Jiandong Huo, Raymond Owens, James Naismith
Narrow Results

Filter by US Classification